Pharma major Lupin on Monday said the US health regulator has issued three observations after inspection of its Tarapur facility in Maharashtra.
The inspection of Tarapur facility was carried out by the United States Food and Drug administration (USFDA) between September 16-20, 2019.
"The inspection at the Tarapur facility closed with three observations," Lupin said in a regulatory filing.
Lupin did not elaborate on the nature of the observations.
"The Company is confident of addressing them satisfactorily," the filing added.
Shares of Lupin were trading 3.52 per cent lower at Rs 729.50 apiece on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)